vs
Side-by-side financial comparison of Stanley Black & Decker (SWK) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $3.8B, roughly 1.3× Stanley Black & Decker). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs 1.4%, a 8.8% gap on every dollar of revenue. On growth, TEVA PHARMACEUTICAL INDUSTRIES LTD posted the faster year-over-year revenue change (11.4% vs 0.1%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $155.3M). Over the past eight quarters, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue compounded faster (11.1% CAGR vs 0.3%).
Stanley Black & Decker, Inc., formerly known as The Stanley Works, is an American manufacturer of industrial tools and household hardware, and a provider of security products. Headquartered in the Greater Hartford city of New Britain, Connecticut, Stanley Black & Decker is the result of the merger of The Stanley Works and Black & Decker on March 12, 2010.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
SWK vs TEVA — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.8B | $4.7B |
| Net Profit | $51.4M | $481.0M |
| Gross Margin | 31.4% | 56.4% |
| Operating Margin | — | 6.4% |
| Net Margin | 1.4% | 10.2% |
| Revenue YoY | 0.1% | 11.4% |
| Net Profit YoY | -43.6% | 321.7% |
| EPS (diluted) | $0.34 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $4.7B | ||
| Q3 25 | $3.8B | $4.5B | ||
| Q2 25 | $3.9B | $4.2B | ||
| Q1 25 | $3.7B | $3.9B | ||
| Q4 24 | $3.7B | $4.2B | ||
| Q3 24 | $3.8B | $4.3B | ||
| Q2 24 | $4.0B | $4.2B | ||
| Q1 24 | $3.9B | $3.8B |
| Q4 25 | — | $481.0M | ||
| Q3 25 | $51.4M | $433.0M | ||
| Q2 25 | $101.9M | $282.0M | ||
| Q1 25 | $90.4M | $214.0M | ||
| Q4 24 | $194.9M | $-217.0M | ||
| Q3 24 | $91.1M | $-437.0M | ||
| Q2 24 | $-11.2M | $-846.0M | ||
| Q1 24 | $19.5M | $-139.0M |
| Q4 25 | — | 56.4% | ||
| Q3 25 | 31.4% | 51.4% | ||
| Q2 25 | 27.0% | 50.3% | ||
| Q1 25 | 29.9% | 48.2% | ||
| Q4 24 | 30.8% | 50.2% | ||
| Q3 24 | 29.9% | 49.6% | ||
| Q2 24 | 28.4% | 48.6% | ||
| Q1 24 | 28.6% | 46.4% |
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 19.7% | ||
| Q2 25 | — | 10.9% | ||
| Q1 25 | — | 13.3% | ||
| Q4 24 | 3.4% | -0.7% | ||
| Q3 24 | 10.6% | -1.2% | ||
| Q2 24 | 9.5% | -0.1% | ||
| Q1 24 | 8.3% | -5.7% |
| Q4 25 | — | 10.2% | ||
| Q3 25 | 1.4% | 9.7% | ||
| Q2 25 | 2.6% | 6.8% | ||
| Q1 25 | 2.4% | 5.5% | ||
| Q4 24 | 5.2% | -5.1% | ||
| Q3 24 | 2.4% | -10.1% | ||
| Q2 24 | -0.3% | -20.3% | ||
| Q1 24 | 0.5% | -3.6% |
| Q4 25 | — | $0.42 | ||
| Q3 25 | $0.34 | $0.37 | ||
| Q2 25 | $0.67 | $0.24 | ||
| Q1 25 | $0.60 | $0.18 | ||
| Q4 24 | $1.29 | $-0.19 | ||
| Q3 24 | $0.60 | $-0.39 | ||
| Q2 24 | $-0.07 | $-0.75 | ||
| Q1 24 | $0.13 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $268.3M | $3.6B |
| Total DebtLower is stronger | $5.3B | — |
| Stockholders' EquityBook value | $9.0B | $7.9B |
| Total Assets | $21.8B | $40.7B |
| Debt / EquityLower = less leverage | 0.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.6B | ||
| Q3 25 | $268.3M | $2.2B | ||
| Q2 25 | $311.8M | $2.2B | ||
| Q1 25 | $344.8M | $1.7B | ||
| Q4 24 | $290.5M | $3.3B | ||
| Q3 24 | $298.7M | $3.3B | ||
| Q2 24 | $318.5M | $2.3B | ||
| Q1 24 | $476.6M | $3.0B |
| Q4 25 | — | — | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.6B | — | ||
| Q1 25 | $5.6B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $6.1B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | — | $7.9B | ||
| Q3 25 | $9.0B | $7.3B | ||
| Q2 25 | $9.1B | $6.8B | ||
| Q1 25 | $8.8B | $6.3B | ||
| Q4 24 | $8.7B | $5.4B | ||
| Q3 24 | $8.9B | $6.1B | ||
| Q2 24 | $8.7B | $6.4B | ||
| Q1 24 | $8.9B | $7.3B |
| Q4 25 | — | $40.7B | ||
| Q3 25 | $21.8B | $39.9B | ||
| Q2 25 | $22.5B | $40.1B | ||
| Q1 25 | $22.5B | $38.4B | ||
| Q4 24 | $21.8B | $39.3B | ||
| Q3 24 | $22.5B | $41.8B | ||
| Q2 24 | $22.5B | $41.3B | ||
| Q1 24 | $23.9B | $42.8B |
| Q4 25 | — | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | 0.63× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.69× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $221.2M | $1.2B |
| Free Cash FlowOCF − Capex | $155.3M | $1.0B |
| FCF MarginFCF / Revenue | 4.1% | 21.6% |
| Capex IntensityCapex / Revenue | 1.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 4.30× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $369.6M | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.2B | ||
| Q3 25 | $221.2M | $369.0M | ||
| Q2 25 | $214.3M | $227.0M | ||
| Q1 25 | $-420.0M | $-105.0M | ||
| Q4 24 | $679.1M | $575.0M | ||
| Q3 24 | $285.8M | $693.0M | ||
| Q2 24 | $573.0M | $103.0M | ||
| Q1 24 | $-431.0M | $-124.0M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $155.3M | $233.0M | ||
| Q2 25 | $134.7M | $131.0M | ||
| Q1 25 | $-485.0M | $-232.0M | ||
| Q4 24 | $564.6M | $446.0M | ||
| Q3 24 | $199.3M | $545.0M | ||
| Q2 24 | $485.8M | $6.0M | ||
| Q1 24 | $-496.7M | $-248.0M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | 4.1% | 5.2% | ||
| Q2 25 | 3.4% | 3.1% | ||
| Q1 25 | -13.0% | -6.0% | ||
| Q4 24 | 15.2% | 10.5% | ||
| Q3 24 | 5.3% | 12.6% | ||
| Q2 24 | 12.1% | 0.1% | ||
| Q1 24 | -12.8% | -6.5% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 1.8% | 3.0% | ||
| Q2 25 | 2.0% | 2.3% | ||
| Q1 25 | 1.7% | 3.3% | ||
| Q4 24 | 3.1% | 3.1% | ||
| Q3 24 | 2.3% | 3.4% | ||
| Q2 24 | 2.2% | 2.3% | ||
| Q1 24 | 1.7% | 3.2% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | 4.30× | 0.85× | ||
| Q2 25 | 2.10× | 0.80× | ||
| Q1 25 | -4.65× | -0.49× | ||
| Q4 24 | 3.48× | — | ||
| Q3 24 | 3.14× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -22.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SWK
| Tools And Outdoor Segment | $3.3B | 87% |
| Engineered Fastening Segment | $500.5M | 13% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
